🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareCost-effectiveness analysis: GLP-1 agonists vs bariatric surgery (ICER 2026) Page 2

Cost-effectiveness analysis: GLP-1 agonists vs bariatric surgery (ICER 2026)

HealthEcon_DC Mon, Mar 2, 2026 at 8:40 PM 15 replies 456 viewsPage 2 of 3
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
Mar 2, 2026 at 11:30 PM#6

This thread is incredible for Cost-effectiveness info. Better than most online groups.

Last edited: Mar 3, 2026 at 4:30 AM
47 13tane_welly, Dr.PathRoch, mona_PHX and 44 others
Reply Quote Save Share Report
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Mar 2, 2026 at 11:47 PM#7

As a healthcare provider, I want to add some clinical context to this discussion on Cost-effectiveness analysis GLP-1.

Building on what wendy_avl said — the evidence base here is well-established. The key publications to reference are from the FLOW program[1].

Key clinical points:

  1. Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
  2. Side effect profile is predictable and usually manageable with standard protocols
  3. Monitoring should include baseline labs and follow-up at 3-month intervals
  4. Patient education significantly improves outcomes and adherence

Standard disclaimer: this is educational, not individualized medical advice.

References:
[1] See thread title for relevant study identification.
31 1hank_denver, carlos_SATX, sophie_paris and 28 others
Reply Quote Save Share Report
hans_munich
Member
534
2,345
Jul 2024
Munich, DE
Mar 3, 2026 at 12:04 AM#8

Reading this thread on Cost-effectiveness hits close to home. Night shift nurse — I started at 295 lbs and felt like I would tried everything.

11 months on tirz and I am a different person. Not just the 70 lbs lost — my energy, my mood, my relationship with food. All transformed.

If you are on the fence about Cost-effectiveness — take the leap. It was the best health decision I have ever made. ❤️

32 2Dr.LipidDallas, alex_tucson, kevin_tulsa and 29 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
CanadaChris
Member
234
890
Nov 2024
Toronto, CA
Mar 3, 2026 at 12:21 AM#9

NurseLeah_Nash — that is really helpful context on Cost-effectiveness. Follow-up question: what labs did your doctor order to monitor this?

I am in a similar situation (just started) and trying to set realistic expectations.

29 0Dr.PulmRoch, maya_sedona, stefan_berlin and 26 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Mar 3, 2026 at 12:38 AM#10

To answer hans_munich's question specifically:

From a clinical standpoint, Cost-effectiveness analysis is an area where we have good evidence.

The short answer: baseline labs + quarterly monitoring is the standard of care.

The longer answer involves understanding the mechanism of action at the receptor level, which I am happy to elaborate on if helpful.

13 3lori_vegas, Dr.PulmRoch, maya_sedona and 10 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register